HEMATOPOIETIC STEM CELL RENEWAL FACTOR

Information

  • Research Project
  • 2029780
  • ApplicationId
    2029780
  • Core Project Number
    R44HL055886
  • Full Project Number
    2R44HL055886-02
  • Serial Number
    55886
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1996 - 28 years ago
  • Project End Date
    1/31/1999 - 25 years ago
  • Program Officer Name
  • Budget Start Date
    2/1/1997 - 27 years ago
  • Budget End Date
    1/31/1998 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    2
  • Suffix
  • Award Notice Date
    1/21/1997 - 27 years ago
Organizations

HEMATOPOIETIC STEM CELL RENEWAL FACTOR

Blood cells are produced by a process known as hematopoiesis. The source of all blood cells is the hematopoietic stem cell (HSC). As the stem cell gives rise to cells which become committed blood cells, they must be renewed or duplicated. Hematopoiesis is regulated by a group of factors known as hematopoietic growth factors. There are factors which affect cells early in development, midway through development, and late in development. These factors act through cell surface receptors to regulate the growth and development of these cells. When there is a need for blood cells, these factors are up-regulated. The factors in turn stimulate an increase of production of the specific blood cell type required. With analogy to the regulation of the other hematopoietic cells development, the renewal of stem cells appears to be under the regulation of a growth factor called stem cell renewal factor (SCRF). During Phase I, novel research tools were developed and an important collaboration was established with an academic laboratory. These developments will enable the goal of isolating the cDNA encoding SCRF to be accomplished in Phase II. In addition, production processes and purification scheme will be developed and animal studies will be performed. SCRF will be useful for the treatment of cancer patients to increase production of blood cell, as a pretreatment to collection of peripheral hematopoietic stem cells for autologous stem cell transplantation, and as an agent to amplify stem cells in culture for stem cell transplantation and gene therapy.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    ICOGENEX CORPORATION
  • Organization Department
  • Organization DUNS
    836856351
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98103
  • Organization District
    UNITED STATES